|Ms. Robin L. Washington||CFO & Exec. VP||2.4M||N/A||1963|
|Dr. John G. McHutchison||Chief Scientific Officer and Head of R&D||2.25M||N/A||1958|
|Mr. Gregg H. Alton||Chief Patient Officer||2.23M||2.94M||1966|
|Ms. Laura Hamill||Exec. VP of Worldwide Commercial Operations||2.34M||N/A||1965|
|Mr. Daniel O'Day||Chairman & CEO||N/A||N/A||1964|
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 3. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 6.